GU Cancers 2022 | Phase I/II study of nivolumab and axitinib for advanced RCC

Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses results from a Phase I/II study (NCT03172754) investigating the use of nivolumab and axitinib for patients with advanced renal cell carcinoma (RCC). Results from the treatment-naïve patient group were presented at ASCO GU 2022. In this patient cohort, there was a complete response rate of 2.4% and an overall response rate of 59%, with a further 38% of patients having stable disease and 1 patient having primary progressive disease. This was not a high-risk group, with 40% of patients having favorable risk and 52% having intermediate risk. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.